Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Selumetinib Boosts ORR in NF1 With Inoperable Plexiform Neurofibroma

November 12th 2024

Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

November 11th 2024

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas

November 10th 2024

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

November 8th 2024

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

November 8th 2024

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma

November 7th 2024

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

November 7th 2024

Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management

November 7th 2024

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

November 5th 2024

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

(Z)-endoxifen Reduces MBD, Is Well Tolerated in Premenopausal Women Screened for Breast Cancer

November 5th 2024

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

Dr Lotan on Ongoing Research With Novel Agents in BCG-Unresponsive NMIBC

November 5th 2024

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC

November 5th 2024

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 5th 2024

The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.

Ongoing Research in Orthopedic Oncology Is Revolutionizing MBD Management

November 5th 2024

R. Lor Randall, MD, FACS, discusses research in orthopedic oncology that is revolutionizing the management of metastatic bone disease from primary cancers.

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

November 4th 2024

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

SHR-A1921 Demonstrates Early Efficacy in Platinum-Resistant Ovarian Cancer

November 3rd 2024

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Research Sheds Light on Gaps in Care Faced by Patients With MBD From Primary Cancers

November 2nd 2024

Secondary metastatic involvement in the musculoskeletal system due to primary cancers and MBD affect patient quality of life and create gaps in care.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.